These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30382051)

  • 1. [Enhancing Antitumor Effects Using Hyperthermia(Including Immune Checkpoint Inhibitor)].
    Takeda T; Kubota Y; Takeda T; Nakano Y; Nogami Y; Honjoh I; Takeda H; Yokoyama Y; Yamamoto H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1479-1481. PubMed ID: 30382051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
    Hamanishi J; Konishi I
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1071-6. PubMed ID: 25248890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) in cancer therapy].
    Hatae R; Chamoto K
    Rinsho Ketsueki; 2016; 57(10):2224-2231. PubMed ID: 27795534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of Immune Checkpoint Inhibitor Combined with Dendritic Cell Therapy and Hyperthermia].
    Takeda T; Kubota Y; Takeda T; Tanaka C; Morita S; Hattori N; Takeda H; Yokoyama Y; Yamamoto H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1472-1474. PubMed ID: 30382049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hyperthemia enhances activated lymphocytes and molecular target therapy].
    Takeda T; Hasegawa T; Miyazawa K; Yoshida K; Takeda T; Takeda H; Takahashi T; Yamamoto I; Kobayashi S
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1924-6. PubMed ID: 22202240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperthermic immuno-cellular therapy-basic and clinical study].
    Takeda T; Fukunaga K; Miyazawa K; Takahashi T; Takeda H; Takeda Y; Tanigawa K; Morisaki T; Yamamoto I; Hasegawa T
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2244-6. PubMed ID: 19106584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging.
    Maute RL; Gordon SR; Mayer AT; McCracken MN; Natarajan A; Ring NG; Kimura R; Tsai JM; Manglik A; Kruse AC; Gambhir SS; Weissman IL; Ring AM
    Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6506-14. PubMed ID: 26604307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
    Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
    BJU Int; 2017 Apr; 119(4):579-584. PubMed ID: 27700015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
    Guo Z; Wang H; Meng F; Li J; Zhang S
    J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response.
    Luo M; Fu L
    Oncotarget; 2016 May; 7(20):29794-803. PubMed ID: 26919108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
    Swaika A; Hammond WA; Joseph RW
    Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of immune checkpoint inhibitors].
    Kitano S
    Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.